

INTERVENTIONS IUCT-Oncopole | ASCO 2023

7 Oral Abstract Session

1 Rapid Abstract Session

3 Clinical Science Symposium

3 Publication only dont 1 en 1 dernier auteur*

23 Poster Session dont 2 en 1^{er} auteur** et 5 en dernier auteur***

3 Poster Discussion Session

Liste des auteurs : Guillaume Bataillon, Sarah Lagarde Bétrian*, Pierre Bories, Clémence Brac de la Perrière, Bastien Cabarrou, Thibaut Cassou Mounat, Christine Chevreau, Ciprian Chira, Florence Dalenc***, Jean-Pierre Delord***, Eleonora De Maio, Nicolas Doumerc, Gwénaél Ferron, Thomas Filleron***, Laurence Gladieff, Gauthier Glemarec, Carlos Gomez Roca**, Benjamin Hébraud, Eva Jouve, Iphigénie Korakis, Jean-Louis Lacaze**, Delphine Larrieu-Cirron, Amélie Lusque, Carole Massabeau, Julien Mazières***, Nicolas Meyer, Elizabeth Moyal, Vincent Nicolai, Lucie Obéric, Cécile Pagès, Anne Pradines, Damien Pouessel, Christian Récher, Vincent Sibaud***, Mony Ung

Oral Abstract Session :

- **Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.**

Luc Cabel, Suzette Delalogue, Anne-Claire Hardy-Bessard, Fabrice Andre, Thomas Bachelot, Ivan Bieche, Celine Callens, Anne Pradines, Florian Clatot, Thibault De La Motte Rouge, Jean-Luc Canon, Laurent Arnould, Barbara Pistilli, Florence Dalenc, Renaud Sabatier, Jean-Marc Ferrero, Alain Lortholary, Jerome Lemonnier, Frederique Berger, Francois Clement Bidard

Organizations

Curie Institute, Gustave Roussy, Medical Oncology, CARIO - HPCA, Medical Oncology, Centre Léon Bérard, Department of Genetics, Institut Curie and University of Paris, Claudius Regaud Institute, Department of Medical Oncology, Centre Henri Becquerel, Eugène Marquis Comprehensive Cancer Center, Grand Hopital De Charleroi, Department of Pathology, Center GF Leclerc, Breast Cancer Unit, Gustave Roussy, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Department of Medical Oncology, Institut Paoli Calmettes, Centre Antoine Lacassagne, Centre Catherine de Sienne, Hôpital Privé du Confluent, R&D Unicancer, Institut Curie, Biostatistics Unit, Institut Curie

Abstract # 1002

- **Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).**

Sara Tolaney, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal Jhaveri, Rosemary Delaney, Theresa Valdez, Oh Kyu Yoon, Hao Wang, Wendy Verret, Hope Rugo

Organizations

Department of Medical Oncology, Dana-Farber Cancer Institute, Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Medical Faculty Mannheim, Heidelberg University, Department of Obstetrics and Gynecology, Medical Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Barts Cancer Institute, Queen Mary University of London, Institut Curie, Medical Oncology Department and D3i, Medical Oncology Department, Centre Léon Bérard, Medical Oncology Department, Hospital 12 de Octubre, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Hospital Universitari Vall D'Hebron, Memorial Sloan Kettering Cancer Center, Gilead Sciences Inc, Gilead Sciences Inc., Department of Medicine, University of California Helen Diller Family Comprehensive Cancer Center

Abstract # 1003

- **Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.**

Howard Safran, Philippe Cassier, Cecile Vicier, Frederic Forget, Carlos Gomez-Roca, Nicolas Penel, Mario Campone, Emanuela Romano, Jennifer Valerin, Guy Jerusalem, Anthony El-Khoueiry, Matt Galsky, Debora Bruno, David Schröder, Mariette Labots, Amy Holdorf, Violetta Kivovich, Jean-Marie Cuillerot, Vivek Subbiah, Stefano Rinaldi

Organizations

Brown University School of Medicine-Rhode Island Hospital, Centre Léon Bérard, Institut Paoli-Calmettes, Centre Hospitalier de l'Ardenne - Site de Libramont, IUCT-Oncopole Toulouse, Centre Oscar Lambret, Institut de Cancérologie de l'Ouest, Institut Curie, Department of Medical Oncology; Center for Cancer Immunotherapy, INSERM U932, PSL, Institut Curie, UC Irvine, CHU Liège and Liège University, USC/Norris Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, University Hospitals, Case Comprehensive Cancer Center, Grand Hopital De Charleroi, Amsterdam UMC location VUMC, Cancer Center Amsterdam, Dragonfly Therapeutics, Inc., The University of Texas MD Anderson Cancer Center

Abstract # 2508

- **In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.**

Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, Aymeric De Montfort, Florence Joly, Isabelle Treilleux, Sarah Ghamry-Barrin, Diana Bello-Roufai, Pierre Saintigny, Antoine Angelergues, Lucas Michon, Anne-Claire Hardy-Bessard, Alexandra Lainé, Aude-Marie Savoye, Justine Berthet, Christophe Caux, Fabrice Lecuru, Bertrand Dubois, Sarah Lagarde Bétrian

Organizations

Centre Léon Bérard, University Claude Bernard Lyon 1, Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan & Team CISTAR, Centre de Recherche en Cancérologie de Lyon INSERM-1052/CNRS-5286/Centre Léon Bérard, Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Department of Medical Oncology, Centre François Baclesse, Centre Léon Bérard, Lyon Immunotherapy for Cancer Laboratory, Centre de Recherche en Cancérologie de Lyon INSERM-1052/CNRS-5286/Centre Léon Bérard, Medical Oncology department, Institut Curie, Centre Léon Bérard and University Claude Bernard Lyon 1, Medical Oncology department, Groupe Hospitalier

Diaconesses Croix Saint-Simon, Medical Oncology, CARIO - HPCA, EMS team, Centre Léon Bérard, Medical Oncology Department, Institut Jean Godinot, Team CISTAR & Lyon Immunotherapy for Cancer Laboratory, Centre de Recherche en Cancérologie de Lyon INSERM-1052/CNRS-5286/Centre Léon Bérard, Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, Institut Claudius Regaud, IUCT-Oncopole

Abstract # 5501

- **Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.**

Clémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, Anne Moreau, Krime Bouabdallah, Gandhi Laurent Damaj, Thomas Gastinne, Olivier Casasnovas, Corinne Haioun, Roch Houot, Eric Van Den Neste, Morgane Cheminant, Herve Ghesquieres, Vincent Ribrag, Franck Morschhauser, Mary Callanan, Remi Gressin, Olivier Hermine, Steven Le Gouill, Fabrice Jardin

Organizations

Institut Curie, Saint Cloud, AP-HP at Saint-Louis Hospital, Hemato-oncology, Paris University, Iuct-Oncopole, CHU Nantes, Department of Hematology, Hôpital du Haut Lévéque, Centre François Magendie, Centre Hosp Universitaire Amiens Sud, Service d'hématologie clinique du CHU de Nantes, CHU Dijon, Henri Mondor's Hospital, Service d'Hématologie Clinique - CHU Pontchaillou, CHU UCL Namur, Necker-Enfants Malades University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Centre de Lutte Contre le Cancer (CLCC), Gustave Roussy (Institut de Cancérologie Gustave-Roussy), CHU Lille - Hopital Huriez, Grenoble University Hospital, Hôpital Necker, APHP, Institut Curie, Department of Hematology, Inserm U918, Centre Henri Becquerel, University of Normandy

Abstract # 7508

- **Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.**

Charles Rudin, Hye Ryun Kim, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csozsi, Delvys Rodriguez-Abreu, Mira Wollner, James Chih-Hsin Yang, Julien Mazieres, Terufumi Kato, Gregory Kalemkerian, Elisha Dettman, Mackenzie Edmondson, Amir Vajdi, Andrey Loboda, Hazem El-Osta, Bin Zhao, Mark Awad, Parneet Cheema

Organizations

Memorial Sloan Kettering Cancer Center, Yonsei Cancer Center, Vall d'Hebron University Hospital, Meir Medical Center, Lausanne University Hospital, Hetenyi G Korhaz Onkologiai Kozpont, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Rambam Medical Center, National Taiwan University Hospital and National Taiwan University Cancer Center, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Kanagawa Cancer Center, University of Michigan, Merck & Co., Inc., Dana-Farber Cancer Institute, William Osler Health System, University of Toronto

Abstract # 8503

- **Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.**

Christian Pfister, Gwenaelle Gravis, Aude Flechon, **Christine Chevreau**, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Yves Allory, Valentin Harter, Stephane Culine
Organizations

Rouen University Hospital, Paoli Calmettes Institute, Léon Bérard Cancer Center, Institut Claudius Regaud/IUCT-Oncopole, Jean Perrin Cancer Center, Department of Medical Oncology, Centre Eugene Marquis, Hôpital Privé de la Loire, Francois Baclesse Cancer Center and GINECO, Institut Curie Saint Cloud (France), Francois Baclesse Cancer Center, Hôpital Saint-Louis - AP-HP

Abstract # LBA4507

Rapid Abstract Session :

- **Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIRO2-Lung/IFCT1301 trial.**

Filippo Dall'Olio, Damien Vasseur, Maryam Karimi, Stefan Michiels, Ludovic Lacroix, Pascale Tomasini, Judith Raimbourg, Noemie pata-Merci, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Ivan Bieche, **Julien Mazieres**, Denis MORO SIBILOT, Marta Jimenez, Jean-Charles Soria, Virginie Westeel, Fabrice Barlesi, Benjamin Besse

Organizations

Cancer Medicine Department, Institut Gustave Roussy, Gustave Roussy, Department of Biostatistics, Gustave Roussy; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Office of Biostatistics and Epidemiology, Gustave Roussy, Assistance Publique Hôpitaux de Marseille (AP-HM), ICO institut de cancerologie de l'ouest, Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France, Institut Curie, Department of Medical Oncology, Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied, Department of Medical Oncology, Institut Paoli-Calmettes, CHITS Toulon Sainte Musse, Pôle de Médecine à Orientation Oncologique, Department of Genetics, Institut Curie and University of Paris, CHU de Toulouse, Pneumology Department, Paul Sabatier University, Centre Hospitalier Universitaire de Grenoble (France), Unicancer, Gustave Roussy Cancer Campus, CHU Besançon, Hôpital J. MINJOZ, Service de Pneumologie, Gustave Roussy and Paris Saclay University, Faculty of Medicine, Gustave Roussy, Villejuif and Paris-Sud University

Abstract # 2516

Clinical Science Symposium :

- **Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).**

Lisa Derosa, Carolina Silva, Valerio Iebba, Bertrand Routy, Anna Reni, Clarisse Audigier-Valette, Gerard Zalcmán, **Julien Mazieres**, Sylvie Friard, François Goldwasser, Denis MORO SIBILOT, Arnaud Scherpereel, Herve Pegliasco, Stéphanie Martinez, Bernard Escudier, David Planchard, Laurence Albiges, Benjamin Besse, Fabrice Barlesi, Laurence Zitvogel

Organizations

Gustave Roussy Cancer Campus, Department of Medical, Surgical and Health Sciences, University of Trieste, Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM (CRCHUM), Université de Montréal, Medical Oncology, Azienda Ospedaliera Universitaria

Integrata di Verona, Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Université Paris Cité, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, CHU de Toulouse, Pneumology Department, Paul Sabatier University, Foch Hospital, Department of Medical Oncology, Hopital Cochin, Université Paris Descartes, CARPEM, APHP, Centre Hospitalier Universitaire de Grenoble (France), CHRU of Lille, Hôpital Européen Marseille, CH du pays D'Aix, Gustave Roussy, Department of Medical Oncology, Department of Medical Oncology, Gustave Roussy, Gustave Roussy, Aix Marseille University - Assistance Publique Hopitaux De Marseille, Gustave Roussy Cancer Campus Grand Paris

Abstract # 103

- **Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.**

Jean-Marc Classe, Pierre Meeus, Eric Leblanc, Romuald Wernert, Francois Quenet, Frédéric Marchal, Gilles Houvenaeghel, Anne-Sophie Bats, Gwenael Ferron, Cecile Brigand, Dominique Berton, Laurence Gladieff, Florence Joly, Isabelle Ray-Coquard, Sylvaine Durand-Fontanier, Gabriel Liberale, Emilie Brument, Bernard Asselain, Loic Campion, Olivier Glehen
Organizations

Institut de Cancérologie Ouest, Centre Léon Bérard, Centre Oscar Lambret, Centre Paul Papin, ICM Val d'Aurelle, Lorraine Cancer Institute, Institut Paoli Calmettes, Hôpital Européen Georges Pompidou, Institut Claudius Regaud, IUCT-Oncopole, CHU Hautepierre, Rene Gauducheau Cancer Center, Francois Baclesse Cancer Center and GINECO, CHU Dupuytren, Institut Jules Bordet, UCGI, Prodige Intergroup, UNICANCER, Arcagy-Gineco, ICO Cancer Center, CRCI2NA, UMR 1307 Inserm-UMR 6075 CNRS, Lyon University hospital, Surgery department

Abstract # 5510

- **An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CTG CX.5-SHAPE).**

Marie Plante, Janice Kwon, Sarah Ferguson, Vanessa Samouëlian, Gwenael Ferron, Amandine Maulard, Cor de Kroon, Willemien Van Driel, John Tidy, Christian Marth, Karl Tamussino, Stefan Kommos, Frederic Goffin, Brynhildur Eyjólfsdóttir, Jae-Weon Kim, Noreen Gleeson, Juliana M Ubi, Lori Brotto, Dongsheng Tu, Lois Shepherd

Organizations

Division of Gynecologic Oncology, Université Laval, CHU de Quebec, University of British Columbia, Pinness Margaret Hospital, Gynecologic Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche de l'Université de Montréal (CRCHUM), Université de Montréal, Institut Claudius Regaud, IUCT-Oncopole, Gustave Roussy Cancer Center, Leiden University Medical Center, Netherlands Cancer Institute, Royal Hallamshire Hospital, Innsbruck Medical University; Department of Obstetrics and Gynecology, Department of Gynecology Medical University Graz, Department of Women's Health, Tübingen University Hospital, CHU de Liege, Oslo University Hospital, Seoul National University College of Medicine, St James' Hospital, Canadian Cancer Trials Group, Queen's University, The University of British Columbia

Abstract LBA5511

Publication only :

- **Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.**
Samir Salah, Delphine Kerob, Cécile Pagès, Mario Lacouture, Vincent Sibaud
Organizations
La Roche-Posay International, Institut Universitaire du Cancer Toulouse-Oncopole, Memorial Sloan Kettering Cancer Center
Abstract # e18885
- **Prediction of brain metastases progression and overall survival in patients with metastatic non-small cell lung cancer treated by immune checkpoint inhibitors using a radiomic model.**
Clemence Henon, Lizza Hendriks, Alexandre Carré, Laura Mezquita, Sylvain Reuzé, Samy Ammari, Mihaela Aldea, Charlotte Robert, Cecile Le Pechoux, Clarisse Audigier-Valette, Julien Mazieres, Corentin Lefebvre, Audrey Rabeau, Boris Duchemann, Angela Botticella, David Planchard, Eric Deutsch, Benjamin Besse, Roger Sun
Organizations
Gustave Roussy, Department of Medical Oncology, Université Paris-Saclay, Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, Gustave Roussy, UMR 1030, ImmunoRadAI, Hospital Clinic - IDIBAPS, Gustave Roussy, Department of Radiology, Gustave Roussy, Department of Medical Oncology, Paris Saclay University, Gustave Roussy, Department of Radiation Oncology, Department of Medical Oncology, CHI de Toulon - Hôpital Sainte-Musse, CHU de Toulouse, Pneumology Department, Paul Sabatier University, Department of Thoracic and Medical Oncology, Avicenne AP-HP, Université Sorbonne Paris Nord, Gustave Roussy, Department of Medical Oncology, Gustave Roussy, Department of Radiation Oncology, UMR 1030, ImmunoRadAI, Gustave Roussy, Gustave Roussy, Department of Radiation Oncology, Université Paris-Saclay, UMR 1030, ImmunoRadAI
Abstract # e21169
- **Comparing PD-L1 scores for predicting pembrolizumab efficacy in first-line treatment of unresectable cutaneous squamous cell carcinomas.**
Eve Maubec, Marouane Boubaya, Lydia Deschamps, Marie Beylot-Barry, Peter Petrow, Isabelle Scheer-Senyarich, Nicole Basset-Seguin, Jean-Jacques Grob, Brigitte Dreno, Coralie Bloch-Queyrat, Marie Leccia, Andreea Raluca Stefan, Philippe Saiag, Florent Grange, Nicolas Meyer, Sophie Dalac, Céline Alloux, Isabelle Lopez, Annick Tibi, Vincent Lévy
Organizations
APHP Hôpital Avicenne, APHP Hôpital Bichat, Hopital Saint-André, Association de Cabinet de Radiologie et d'Imagerie Médicale, Polyclinique Saint-Côme, APHP Hôpital Saint-Louis, Hôpital de la Timone, Service Oncodermatologie, Dermatology Department, CHU Albert Michallon, Grenoble; Université de Grenoble, Hopital Clemenceau, APHP Hôpital Ambroise Paré, Centre Hospitalier de Valence, Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), CHU de Dijon, APHP AGEPS
Abstract # e21593

Poster session :

- **Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.**

Sylvie Giacchetti, Enora Laas, Thomas Bachelot, Jerome Lemonnier, Fabrice Andre, David Cameron, Judith Bliss, Sylvie Chabaud, Anne-Claire Hardy-Bessard, Magali Lacroix-Triki, Jean-Luc Canon, Marc Debled, Mario Campone, Paul Cottu, **Florence Dalenc**, Annabelle Ballesta, Frederique Penault-Llorca, Fabien Reyal, Francis Lévi, Anne-Sophie Hamy

Organizations

APHP University Hopital Saint Louis, Senopole, Surgery Department, Institut Curie, Universite Paris Cite, Medical Oncology, Centre Léon Bérard, R&D Unicancer, Institut Gustave Roussy, Edinburgh University Cancer Centre, Medical Oncology, Western General Hospital, Department of Clinical Research and Innovation, Centre Léon Bérard, Medical Oncology, CARIO - HPCA, Gustave Roussy, Medical Oncology, Grand Hopital de Charleroi, Medical Oncology, Institut Bergonie, Medical Oncology, Institut Cancerologie de l'Ouest, Medical Oncology, Institut Curie, Universite, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Inserm Unit 900, Institut Curie, MINES ParisTech CBIO - Centre for Computational Biology, PSL Research University, Pathology department, Centre Jean Perrin, Surgery Department, Institut Curie, Universite Paris, Chronotherapy, Cancers, and Transplantation Unit, Faculty of Medicine, Paris-Saclay University, Medical Oncology, Institut Curie, Universite Paris Cite

Abstract # 546

Poster Bd # 376

- **Prognostic factors in hormone receptor positive oligometastatic breast cancer.**

Lacaze Jean Louis, Bastien Cabarrou, Gauthier Glemarec, Clémence Brac de la Perrière, Thibaut Cassou Mounat, Ciprian Chira, Eleonora De Maio, Eva Jouve, Carole Massabeau, Vincent Nicolai, Mony Ung, Florence Dalenc

Organizations:

Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département d'Oncologie médicale, Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Institut Claudius Regaud, IUCT - Oncopole, Iuct-Oncopole, Institut Claudius Regaud, IUCT-Oncopole, Institut Claudius Regaud, IUCT-Oncopole.fr, CHU Toulouse, Institut Claudius Regaud (ICR), Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole

Abstract # 1058

Poster Bd # 279

- **Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPitello-291 trial.**

Hope Rugo, Mafalda Oliveira, Sacha Howell, **Florence Dalenc**, Javier Cortes, Henry Gomez, Xichun Hu, Hiroji Iwata, Komal Jhaveri, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Lyudmila Zhukova, Jill Logan, Ken Twomey, Mahmuda Khatun, Celina D'Cruz, Nicholas Turner

Organizations

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), The University of Manchester, Manchester, United Kingdom and The Christie NHS Foundation Trust, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain, Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Instituto Nacional de Enfermedades Neoplásicas (INEN), Departamento de Oncología Médica and Universidad Ricardo Palma, Fudan University Shanghai Cancer Center, Aichi Cancer Center Hospital, Memorial Sloan Kettering Cancer Center New York, NY, USA and Weill Cornell Medical College, GBG Forschungs GmbH, Neu-Isenburg, Germany and Centre for Haematology and Oncology, Bethanien, Institut de Recerca Biomèdica, ICON Cancer Centre, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Yonsei Cancer Center, Yonsei University College of Medicine, Loginov Moscow Clinical Scientific Center, Oncology R&D, AstraZeneca, Royal Marsden Hospital, Institute of Cancer Research

Abstract # 1067

Poster Bd # 288

- **Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).**

Virginia Kaklamani, Francois Clement Bidard, Patrick Neven, Alberto Montero, Marie-Ange Mouret-Reynier, Joohyuk Sohn, Donatienne Taylor, Frederic Forget, Kathleen Harnden, Hung Khong, Judit Kocsis, **Florence Dalenc**, Patrick Dillon, Simon Waters, José García-Sáenz, Philippe Aftimos, Javier Cortes, Simona Scartoni, Nassir Habboubi, Aditya Bardia

Organizations

UT Health San Antonio, Institut Curie, Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, University Hospitals Seidman Cancer Center, Jean Perrin Cancer Centre, Yonsei Cancer Center, Yonsei University College of Medicine, Université Catholique de Louvain, CHU UCL Namur – Site Sainte-Elisabeth, Centre Hospitalier de l'Ardenne - Site de Libramont, Inova Schar Cancer Institute, Moffitt Cancer Center, Bacs Kiskun Megyei Korhaz, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, University of Virginia, Velindre Cancer Centre, Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium, International Breast Cancer Centre (IBCC), Pangaea Oncology, Quironsalud Group, Menarini Group, Stemline Therapeutics/Menarini Group, Massachusetts General Hospital Cancer Center

Abstract # 1070

Poster # 291

- **Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.**

Dinu Stefan, Justine Lequesne, Sunyach Marie, **Delphine Larrieu-Ciron**, Charlotte Bronnimann, Loic Feuvret, Julien Geffrelot, Jeanne Riverain, Pierre-Emmanuel Brachet, Joelle Lacroix, Fernand Missohou, Maxime Faisant, Evelyne Emery, **Elisabeth Moyal**, Bérénice Legrand, Gwenaëlle Boudier, Marie Castera, Jean-Michel Grellard, Paul Lesueur, Benedicte Clarisse

Organizations:

Centre François Baclesse, Radiation Oncology Department, Centre François Baclesse, Clinical Research Department, Centre Léon Berard, Radiation Oncology Department, Cancer University Institute of Toulouse - Oncopole, University Hospital, CHU Bordeaux, Radiation Oncology Department, Hospices Civils de Lyon (HCL), Groupe Est, Lyon, Centre François Baclesse, Department of Medical Oncology, Centre François Baclesse, Radiology Department, University Hospital, Caen, Department of Pathology, University hospital, Department of Neurosurgery, Institut Universitaire du Cancer de Toulouse-Oncopole

Abstract # 2046

Poster Bd # 403

- **Phase I study of MP0317, a FAP-dependent DARPIn, for tumor-localized CD40 activation in patients with advanced solid tumors.**

Carlos Gomez-Roca, Neeltje Steeghs, Eelke Gort, Hilde De Winter, Elena Fernandez, Vaia Stavropoulou, Nina Stojcheva, Paul Baverel, Jennifer Krieg, Kyriaki Ioannou, Ana Florescu, Patrick Mossi, Lea Hoenig, Bruno Baud-Berthier, Vladimir Kirkin, Anne Goubier, Philippe Legenne, Philippe Cassier

Organizations

Institut Claudius Regaud, IUCT-Oncopole, The Netherlands Cancer Institute, UMC Utrecht, Molecular Partners AG, Centre Léon Bérard

Abstract # 2584

Poster Bd # 426

- **Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).**

Christophe Le Tourneau, Frédéric Bigot, Damien Vansteene, Maud Kamal, François Ghiringhelli, Luca Mazarella, Christian Borel, Raphael Chaltiel, Benoit You, **Carlos Gomez-Roca**, Sophie Cousin, Elodie Coquan, Aurélien Lambert, Esma Saada-Bouzid, Xavier Durando, François Legrand, **Amelie Lusque**, Fabrice Andre, **Thomas Filleron**

Organizations

Curie Institute, Institut de Cancerologie de l'Ouest, ICO Institut de Cancerologie de l'Ouest, Drug Development and Innovation Department, Institut Curie, Center Georges-Francois Leclerc, IEO, European Institute of Oncology IRCCS, Centre Paul Strauss, Institut Godinot, Lyon Sud Hospital, Institut Claudius Regaud, IUCT-Oncopole, Medical Oncology Department, Institut Bergonié, Centre François Baclesse, Institut De Cancerologie De Lorraine, Centre de Lutte Contre le Cancer Antoine Lacassagne, Centre de Lutte contre le Cancer, Unicancer, IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, Gustave Roussy, Institut Universitaire du Cancer Oncopole - Institut Claudius Regaud

Abstract # 2597

Poster Bd # 439

- **Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.**

Christelle De La Fouchardiere, **Carlos Gomez-Roca**, Aymeric De Montfort, Antoine Italiano, Marine Gilibert, Olivier Tredan, **Iphigénie Korakis**, Isabelle Ray-Coquard, Pauline Rochefort, Armelle

Dufresne, Sophie Cousin, Christophe Le Tourneau, Benoit You, Francois Bertucci, Philippe Cassier, Valéry Attignon, Romaine Mayet, Gwenaelle Garin, David Pérol, Jean-Yves Blay
Organizations

Medical Oncology Department, Centre Leon Berard, Lyon I University, IUCT-Oncopole Toulouse, Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Institut Bergonié, Institut Paoli calmettes, Medical Oncology Department, Centre Léon Bérard, IUCT Oncopole Toulouse, Centre Léon Bérard, Centre Leon Berard, Medical Oncology Department, Institut Bergonié, Institut Curie, Lyon Sud Hospital, Institut Paoli-Calmettes

Abstract # 2604

Poster Bd # 446

- **Immunogenicity and clinical activity of tipapkinogen sovavivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.**

Christophe Le Tourneau, Frederic Rolland, Olivier Capitain, Amaury Daste, Philippe Cassier, Sebastien Salas, Luis Manso Sánchez, Antonio Casado Herraes, Gerardo Colon-Otero, Lauriane Eberst, Camille Jamet, Ana Lalanne, Olivier Lantz, Hakim Makhoulfi, Annette TAVERNARO, Kaidre Bendjama, Maud Brandely-Talbot, **Jean-Pierre Delord**

Organizations

Institut Curie, Ico Institut de Cancerologie de l'Ouest, Department of Medical Oncology, Hôpital Saint-André, University of Bordeaux-CHU Bordeaux, Centre Léon Bérard, CEPCM Assistance Publique des Hôpitaux de Marseille, Aix-Marseille Université, Department of Medical Oncology, Hospital Universitario 12 de Octubre, Hospital Universitario San Carlos, Mayo Clinic, Institut de Cancérologie de Strasbourg, Transgene SA, IUCT Oncopole

Abstract # 2630

Poster Bd # 472

- **Disease-free survival in operated patients with nmRCC using machine learning.**

Gaëlle Margue, Loïc Ferrer, Guillaume Etchepare, Pierre Bigot, Karim Bensalah, Arnaud Mejean, Morgan Roupret, **Nicolas Doumerc**, Alexandre Ingels, Romain Boissier, Geraldine Pignot, Bastien Parier, Philippe Paparel, Thibaut Waeckel, Thierry Colin, Jean-Christophe Bernhard

Organizations

Department of Urology, Bordeaux University Hospital, SOPHiA GENETICS, Centre Hospitalier Universitaire d'Angers, Service d'Anatomie et cytologie Pathologique - CHU Pontchaillou, Department of Urology, Hôpital Européen Georges-Pompidou - Paris Descartes University, Hôpital Pitié-Salpêtrière, Toulouse University Hospital, Department of Urology, University Hospital Henri Mondor, APHP, Department of Urology and Renal transplantation, La Conception University Hospital, APHM, Institut Paoli-Calmettes, CHUde Bicetre, Service d'urologie CHU Lyon Sud, Université de Lyon, Caen University Hospital, CHU Bordeaux

Abstract # 4539

Poster Bd # 31

- **Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.**

Yohann Lorient, Arjun Balar, Daniel Petrylak, Arash Rezazadeh, Petros Grivas, Aude Flechon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthelemy, Philippe Beuzeboc, Phillip

Palmbos, Christos Kyriakopoulos, **Damien Pouessel**, Cora Sternberg, Julia Tonelli, Emon Elboudwarej, Lauri Diehl, Juliane Jürgensmeier, Scott Tagawa

Organizations

Institut de Cancérologie Gustave Roussy, Perlmutter Cancer Center at NYU Langone Health, Smilow Cancer Center, Yale School of Medicine, University of California Irvine, University of Washington; Fred Hutchinson Cancer Center, Centre Léon Bérard, H. Lee Moffitt Cancer Center and Research Institute, Huntsman Cancer Institute (NCI-CCC), University of Utah, Rocky Mountain Cancer Centers, Hôpitaux Universitaires de Strasbourg, Institut de Cancérologie Strasbourg Europe, Hôpital Foch, University of Michigan, University of Wisconsin Carbone Cancer Center, Institut Claudius Régaud/IUCT-Oncopole, Weill Cornell Medicine, Gilead Sciences, Inc., Gilead Sciences, Inc.

Abstract # 4579

Poster Bd # 71

- **BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.**

Helene Blons, Justine Abdelli, Valerie Taly, Claire Mulot, Pierre Laurent Puig, Benoit You, Philipp Harter, Domenica Lorusso, Yolanda Garcia, Christian Schauer, Sakari Hietanen, Nicoletta Colombo, Ignace Vergote, Hiroaki Kobayashi, Thibault De La Motte Rouge, Paul Buderath, Sabrina Cecere, **Guillaume Bataillon**, Eric Pujade-Lauraine, Isabelle Ray-Coquard

Organizations

APHP, European Georges Pompidou Hospital, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Paris Cancer Institute CARPEM, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, INSERM, Team Personalized Medicine, Pharmacogenomics and Therapeutic Optimization (MEPPOT), Department of genetics and molecular medicine, Georges Pompidou European hospital, APHP Centre, Centre Hospitalier Lyon Sud, Pierre-Benite and GINECO, Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, and AGO, Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of Sacred Heart, and MITO, Parc Taulí Hospital Universitari, and GEICO, Hospital Barmherzige Brüder Graz, and AGO Aut, Department of Gynecologic Oncology, Turku University Hospital, and NSGO, Department of Medicine and Surgery, University of Milan-Bicocca and Gynecologic Oncology Program, European Institute of Oncology IRCCS, and MANGO, University Hospital Leuven, Leuven Cancer Institute, Belgium, European Union, and BGOG, Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, and GOTIC, Centre Eugène Marquis, Rennes, and GINECO, Universitätsklinikum Essen, Frauenklinik, and AGO, Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and MITO, Department of Pathology, Oncopole University Hospital Toulouse, ARCAGY Research, Centre Léon Bérard, Lyon and GINECO

Abstract # 5559

Poster Bd # 254

- **Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.**

Christian Ottensmeier, **Jean-Pierre Delord**, Ana Lalanne, Olivier Lantz, Camille Jamet, Annette TAVERNARO, Maud Brandely-Talbot, Benoît Grellier, Berangere Bastien, Hakim Makhoulfi, Thierry

Huss, Yoshiko Yamashita, Kousuke Onoue, Naoko Yamagata, Yuki Tanaka, Brandon Malone, Oliver Baker, Eric Quemeneur, Kaidre Bendjama, Christophe Le Tourneau
Organizations

The Clatterbridge Cancer Centre NHS Foundation Trust, IUCT Oncopole, Institut Curie, Transgene SA, Transgene, Transgene S.A., NEC Corporation, NEC Oncoimmunity, NEC Laboratories Europe GmbH

Abstract # 6082

Poster Bd # 74

- **Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias.**

Sylvain Garciaz, Pierre Bories, Leonor Lopez Almeida, Jean-Marie Boher, Coralie Belanger, Christian Recher, Olivier Hermine, Norbert Vey, Pierre Launay

Organizations

Institut Paoli-Calmettes, Aix-Marseille University, Institut Universitaire du Cancer Toulouse, Institut Paoli Calmettes, Paoli Calmettes Institute, Inatherys, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Institut Paoli-Calmettes

Abstract # 7045

Poster Bd # 175

- **Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).**

Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frederic Peyrade, Roch Houot, Christine Foulon, Estelle Chauvin, Herve Ghesquieres, Carole Soussain

Organizations

Institut Curie, Institut Curie, Biostatistics Unit, Centre Henri-Becquerel and University of Rouen, Bergonié Institute, Neurology, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Iuct-Oncopole, CHU Timone, Hôpital Claude Huriez Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées and Centre Hospitalier Régional Universitaire de Lille, CentreAntoineLacassagne, Service d'Hématologie, CHU de Rennes, Inserm U1236 Université de Rennes 1, DREH Pôle Promotion, Institut Curie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud

Abstract # 7566

Poster Bd # 117

- **Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).**

Cyrille Touzeau, Xavier Leleu, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulmann, Caroline Lenoir, Pascal Godmer, Agathe Farge, Laure Peyro Saint Paul, Jean-Jacques Parienti, Margaret Macro

Organizations

University Hospital of Nantes, France, Centre Hospitalier Universitaire de Poitiers, CHU Grenoble, Lille University Hospital, APHP Hôpital Avicenne, Montpellier University Hospital, Cancer University Institute of Toulouse - Oncopole, University Hospital, CHU Nancy, Polyclinique Bordeaux Nord Nord Aquitaine, GHBA, IHBN, CHU, CHU, CHU Caen, University of Caen Hospital Centre

Abstract # 8054

Poster Bd # 46

- **Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study**

Paul Paik, Marina Garassino, Xiuning Le, Michael Thomas, Hiroshi Sakai, Remi Veillon, Egbert Smit, Julien Mazieres, Alexis Cortot, Jo Raskin, Santiago Viteri, James Chih-Hsin Yang, Myung-Ju Ahn, Yi-Long Wu, Jun Zhao, Svenja Adrian, Karin Berghoff, Rolf Bruns, Andreas John, Enriqueta Felip
Organizations

Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Department of Thoracic Oncology, Ageo Central General Hospital, CHU Bordeaux, Service Des Maladies Respiratoires, Department of Pulmonary Diseases, Leiden University Medical Centre, CHU de Toulouse, Université Paul Sabatier, Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 – UMR-S 1277 - Canther, Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital (UZA), UOMI Cancer Center, Clínica Mi NovAliança, Department of Medical Oncology, National Taiwan University Cancer Center, Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Global Clinical Development, the healthcare business of Merck KGaA, Global Patient Safety, the healthcare business of Merck KGaA, Department of Biostatistics, the healthcare business of Merck KGaA, Department of Oncology, Vall d'Hebron Institute of Oncology (VHIO)

Abstract # 9060

Poster Bd # 48

- **Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.**

Xiuning Le, Anna Eisert, Te-Chun Hsia, Nirmal Raut, Azura Ahmad, Oscar Chan, Charlotte De Bondt, David Farrugia, Patrizia Froesch, Maria González-Cao, Lizza Hendriks, Maximilian Hochmair, Julien Mazieres, Hazel O'Sullivan, Jens Samol, Anthonie van der Wekken, Tsung-Ying Yang, Kirti Joshi, Soetkin Vlassak, Gee-Chen Chang
Organizations

Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn

Cologne Duesseldorf, University Hospital of Cologne, China Medical University Hospital, Bhaktivedanta Hospital And Research Centre and School of Consciousness, MIT WPU, Beacon Hospital, Department of Clinical Oncology, Hong Kong Integrated Oncology Centre, Department of Thoracic Oncology, Antwerp University Hospital, Gloucestershire Oncology Centre, Cheltenham General Hospital, Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Klinik Floridsdorf, CHU de Toulouse, Pneumology Department, Paul Sabatier University, Lung Unit, Royal Marsden NHS Foundation Trust, Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, Asst Prof Johns Hopkins University, US, Asst Prof Lee Kong Chian/NTU, Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Division of Chest Medicine, Taichung Veterans General Hospital, Global Development Operations, the healthcare business of Merck KGaA, Darmstadt, Germany; ICON plc, Global Medical Affairs, Merck N.V.-S.A., Belgium, an affiliate of Merck KGaA, Department of Internal Medicine, Chung Shan Medical University Hospital

Abstract # 9070

Poster Bd # 58

- **Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.**

Helena Yu, Keith Kerr, Christian Rolfo, Jian Fang, Giovanna Finocchiaro, Kam-Hung Wong, Remi Veillon, Terufumi Kato, James Chih-Hsin Yang, Ernest Nadal, Jo Raskin, Xiuning Le, Niki Karachaliou, Barbara Ellers-Lenz, Aurora OBrate, Christopher Stroh, Nadine Piske, Carsten Boesler, Jinji Yang, **Julien Mazieres**

Organizations

Memorial Sloan Kettering Cancer Center, Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Foresterhill, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Department of Thoracic Oncology, Peking University Cancer Hospital, IRCCS Humanitas Research Hospital, Rozzano, Department of Clinical Oncology, Queen Elizabeth Hospital, CHU Bordeaux, Service Des Maladies Respiratoires, Department of Thoracic Oncology, Kanagawa Cancer Center, Department of Medical Oncology, National Taiwan University Cancer Center, Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital (UZA), Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Global Clinical Development, the healthcare business of Merck KGaA, Department of Biostatistics, the healthcare business of Merck KGaA, Global Medical Affairs, the healthcare business of Merck KGaA, Companion Diagnostics & Biomarker Strategy, the healthcare business of Merck KGaA, Clinical Biomarkers & Technologies, the healthcare business of Merck KGaA, Department of Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, CHU de Toulouse, Université Paul Sabatier

Abstract # 9074

Poster Bd # 62

- **Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.**

Astrid Blom Fily, Laurent Mortier, Isabelle Kachaner, **Nicolas Meyer**, Mahtab Samimi, Laura Luciani, Capucine Cahuzac, Caroline Robert, Gaëlle Quéreux, Eve Maubec, Cathy Maillard, Hakima Miotti, François Aubin, Cédric Lenormand, Marie-Noelle Solbes, Pascal Joly, Benoît van Hille, Celeste Lebbe, Caroline Dutriaux, Philippe Saiag

Organizations

CHU Ambroise Paré, Hôpital Claude Huriez, CHU de Lille, Pfizer, CHU de Toulouse, CHRU de Tours, Hôpital Trousseau, Tours, France; ISP 1282 INRA University of Tours, Merck Santé S.A.S., Lyon, France, an affiliate of Merck KGaA, Institut Gustave Roussy, CHU de Nantes, Hôpital Hôtel-Dieu, Hôpital Avicenne – APHP, IQVIA Opérations France, CHU et Inserm 1098, Dermatologie, MCU-PH, Service de Dermatologie, Hôpitaux Universitaires de Strasbourg, CHU de Rouen, Hôpital Charles-Nicolle, Merck Santé S.A.S, an affiliate of Merck KGaA, Université Paris Cité, Dermato-Oncology, CIC AP-HP Hôpital Saint-Louis; INSERM U976, CHU de Bordeaux, Hôpital Saint-André, CHU Ambroise-Paré

Abstract # 9537

Poster Bd # 300

- **Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfILER 02 trial.**

Mehdi Brahmi, Olivier Tredan, Nicolas Penel, **Christine Chevreau**, Christophe Perrin, Nelly Firmin, Emmanuelle Bompas, François Bertucci, Valéry Attignon, Pierre Saintigny, Isabelle Treilleux, Sylvie Chabaud, Gwenaëlle Garin, David Pérol, Jean-Yves Blay, Armelle Dufresne

Organizations

Centre Léon-Bérard, Medical Oncology Department, Centre Léon Bérard, Department of Medical Oncology, Centre Oscar Lambret, Institut Claudius Regaud/IUCT-Oncopole, Centre Eugène Marquis, ICM VAL D'AURELLE, René Gauducheau Cancer Center, Institut Paoli-Calmettes, Centre Léon Bérard, Centre Léon Bérard - Cancer Research Center of Lyon, Centre Léon Bérard, Department of Clinical Research and Innovation, Centre Léon Bérard

Abstract # 11545

Poster Bd # 479

- **Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).**

Martina Pagliuca, Julie Havas, Florence Lerebours, Olivier Rigal, Thierry Petit, Sylvie Giacchetti, **Florence Dalenc**, Johanna Wassermann, Olivier Arsene, Anne-Laure Martin, Sibille Everhard, Ines Maria Luis, Antonio Di Meglio

Organizations

INSERM Unit 981, Gustave Roussy, Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy, Institut Curie, Centre Henri Becquerel, Institut of Cancer Strasbourg (ICANS), APHP University Hospital Saint Louis, Senopole, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Hôpital Pitié-Salpêtrière, Centre Hospitalier, Unicancer, Gustave Roussy, Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy

Abstract # 12087

Poster Bd # 455

- **TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.**

Alexandra Leary, Laurence Gladieff, Renaud Sabatier, Xavier Paoletti, Frederik Marmé, Toon Van Gorp, Jerome Alexandre, Thomas Grellety, Antoine Angelergues, Victor Simmet, Julien Grenier, Paule Augereau, Michel Fabbro, Pierre Combe, Anne-Claire Hardy-Bessard, Emilie Kaczmarek
Organizations

Gustave-Roussy Cancer Campus, Villejuif, and GINECO, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, and GINECO, Institut Paoli Calmettes, Marseille, and GINECO, Biostatistic Unit, Institut Curie and GINECO, Medical Faculty Mannheim, Heidelberg University & AGO Study Group, Leuven Cancer Institute, University Hospital Leuven, and BGOG, Université de Paris Cité, AP-HP, Hôpital Cochin, Paris, and GINECO, Centre Hospitalier de la Côte Basque, Groupe Hospitalier Diaconesses Croix Saint-Simon, Centre Hospitalier de Cholet, Cholet, and GINECO, Institut du Cancer Avignon-Provence, Avignon, and GINECO, Institut de Cancérologie de l'Ouest, Centre Paul Papin, Angers, and GINECO, Institut du Cancer de Montpellier (ICM), Montpellier, and GINECO, Pôle santé Léonard de Vinci, Centre d'oncologie et radiothérapie, ROC37, Tours, and GINECO, Centre CARIO – HPCA, Plérin Sur Mer, and GINECO, Centre Oscar Lambret, Lille, and GINECO

Abstract # TPS5618

Poster Bd # 310a

Poster Discussion session :

- **Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.**

Jean-Sebastien Frenel, Jean Zeghondy, Catherine Guerin, Audrey Mailliez, Elsa Volant, Francois Pomeaud, Anne Patsouris, Monica Arnedos, Caroline Bailleux, Julie Cabal, Loick Galland, Alexandre De nonneville, Severine Guiu Lahaye, Florence Dalenc, Barbara Pistilli, Thomas Bachelot, Pierre Martin, Francois Bocquet, Louis Larrouquere, Delphine Loirat

Organizations

Institut de Cancerologie de l'Ouest, Gustave Roussy Cancer Center, ICO institut de cancerologie de l'ouest, Oscar Lambret Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, CHU Toulouse, Institut de Cancerologie de L'Ouest, Institut Bergonie, Centre Antoine Lacassagne, Centre Eugene Marquis, Centre Georges Francois Leclerc, Institut Paoli Calmette, Montpellier Cancer Institute, Claudius Régaud Institute, Breast Cancer Unit, Gustave Roussy, Medical Oncology, Centre Léon Bérard, Institut Curie, Institut de Cancérologie Ouest, Centre Leon Berard, Institut Curie, Medical Oncology Department and D3i

Abstract # 1014

Poster Bd # 235

- **Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.**

Stéphane De Botton, Pau Montesinos, Susana Vives Polo, Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo Calado, Andre Schuh, Su-Peng Yeh, Jianan Hui, Diego Gianolio, Prapti Patel, **Christian Recher**, Hartmut Dohner

Organizations

Institut Gustave Roussy, Hospital Universitario y Politecnico La Fe, ICO-Hospital Germans Trias i Pujol, Medical University of Gdansk, Peking Union Medical College Hospital, ASST Grande Ospedale Metropolitano Niguarda, Hannover Medical School, Ribeirão Preto School of Medicine, University of São Paulo, Princess Margaret Cancer Centre, China Medical University Hospital, Servier Pharmaceuticals LLC, Servier Pharmaceuticals, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncople, Ulm University

Abstract # 7012

Poster Bd # 142

- **Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.**

Daniel Tan, Tae Min Kim, Valentina Guarneri, PEI JYE VOON, Boon Khaw Lim, Marie Wislez, Cheng Huang, Chong Kin Liam, **Julien Mazieres**, Lye Tho, Hidetoshi Hayashi, Nguyen Nhung, Puey Chia, Filippo de Marinis, Xiuning Le, Niki Karachaliou, Sabine Brutlach, Barbara Eilers-Lenz, Yi-Long Wu, Svenja Adrian

Organizations

Division of Medical Oncology, National Cancer Centre, Seoul National University Cancer Research Institute, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Hospital Umum Sarawak, Kuching, Department of Medicine, Faculty of Medicine, University of Malaya, Service de Pneumologie, Hopital Cohin, Assistance Publique – Hôpitaux de Paris, Department of Thoracic Oncology, Fujian Cancer Hospital, CHU de Toulouse, Pneumology Department, Paul Sabatier University, Department of Oncology, Pantai Hospital Kuala Lumpur, Department of Medical Oncology, Kindai University Faculty of Medicine, National Lung Hospital, Department of Medical Oncology, Tan Tock Seng Hospital, Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Global Clinical Development, the healthcare business of Merck KGaA, Global Development Operations, the healthcare business of Merck KGaA, Department of Biostatistics, the healthcare business of Merck KGaA, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University

Abstract # 9021

Potsre Bd # 9